Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of Patiromer in Heart Failure Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jun 2021
Price :
$35
*
At a glance
- Drugs Patiromer (Primary)
- Indications Hyperkalaemia
- Focus Therapeutic Use
- Acronyms PEARL-HF
- Sponsors Relypsa
- 23 May 2012 Additional lead trial investigator (Yuri Stasiv) identified as reported by ClinicalTrials.gov.
- 14 Apr 2012 Planned number of patients 270 added as reported by European Clinical Trials Database.
- 16 Sep 2010 Primary endpoint 'Potassium levels' has been met.